Celgene has acquired Gloucester Pharmaceuticals for US$340 million upfront and up to $300 million in milestones. Through the deal, Celgene gains Gloucester's romidepsin (Istodax), a histone ...

In contrast, in the new trial combining an HDAC inhibitor with the immunotherapy, 3 of 27 patients had deep tumor shrinkage from the drug combination. In future studies, the team hopes to ...

Italfarmaco's marketing application for HDAC inhibitor givinostat as a treatment ... The Milan-based drugmaker filed for approval of the drug in the US earlier this year, with a priority review ...

In contrast, in the new trial combining an HDAC inhibitor with the immunotherapy, 3 of 27 patients had deep tumor shrinkage from the drug combination. In future studies, the team hopes to ...

20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development ... data expected in H1 2025 REC-2282 (pan-HDAC inhibitor; Neurofibromatosis Type 2): PFS6 ...